Patents by Inventor Christian Taube

Christian Taube has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9999660
    Abstract: The present invention is directed to polypeptides and compositions thereof useful for the prevention and treatment of allergic disorders, in particular atopic asthma. More particularly, the invention relates to tolerogenic agents and compositions thereof that are useful for the prevention and treatment of hypersensitivity to allergens, in particular strategies of desensitization to allergens.
    Type: Grant
    Filed: January 30, 2015
    Date of Patent: June 19, 2018
    Assignees: UNIVERSITAT ZURICH, LEIDEN UNIVERSITY MEDICAL CENTER
    Inventors: Anne Mueller, Daniela Engler-Anders, Christian Taube
  • Publication number: 20170007683
    Abstract: The present invention is directed to polypeptides and compositions thereof useful for the prevention of treatment of allergic disorders, in particular atopic asthma. More particularly, the invention relates to tolerogenic agents and compositions thereof that are useful for the prevention and treatment of hypersensitivity to allergens, in particular and/or strategies of desensitization to allergens.
    Type: Application
    Filed: January 30, 2015
    Publication date: January 12, 2017
    Inventors: Anne Mueller, Daniela Engler-Anders, Christian Taube
  • Publication number: 20140154307
    Abstract: Disclosed are novel inhibitors of the alternative complement pathway and particularly, novel anti-factor B antibodies. Also disclosed is the use of such inhibitors to reduce or prevent airway hyperresponsiveness and/or airway inflammation by selectively inhibiting the alternative complement pathway, thereby treating diseases in which such conditions play a role. Also disclosed is the use of such inhibitors to reduce or prevent other diseases and conditions, including ischemia-reperfusion injury, by inhibition of the alternative complement pathway.
    Type: Application
    Filed: February 18, 2014
    Publication date: June 5, 2014
    Applicants: MUSC Foundation for Research Development, National Jewish Health, The Regents of the University of Colorado, a body corporate
    Inventors: V. Michael HOLERS, Joshua M. Thurman, Christian Taube, Erwin W. Gelfand, Gary Steven Gilkeson
  • Patent number: 8703140
    Abstract: Disclosed are novel inhibitors of the alternative complement pathway and particularly, novel anti-factor B antibodies. Also disclosed is the use of such inhibitors to reduce or prevent airway hyperresponsiveness and/or airway inflammation by selectively inhibiting the alternative complement pathway, thereby treating diseases in which such conditions play a role. Also disclosed is the use of such inhibitors to reduce or prevent other diseases and conditions, including ischemia-reperfusion injury, by inhibition of the alternative complement pathway.
    Type: Grant
    Filed: August 22, 2007
    Date of Patent: April 22, 2014
    Assignees: MUSC Foundation for Research Development, National Jewish Health, The Regents of the University of Colorado, a body corporate
    Inventors: V. Michael Holers, Joshua M. Thurman, Christian Taube, Erwin W. Gelfand, Gary Gilkeson
  • Patent number: 8652475
    Abstract: Disclosed are novel inhibitors of the alternative complement pathway and particularly, novel anti-factor B antibodies. Also disclosed is the use of such inhibitors to reduce or prevent airway hyperresponsiveness and/or airway inflammation by selectively inhibiting the alternative complement pathway, thereby treating diseases in which such conditions play a role. Also disclosed is the use of such inhibitors to reduce or prevent other diseases and conditions, including ischemia-reperfusion injury, by inhibition of the alternative complement pathway.
    Type: Grant
    Filed: August 3, 2007
    Date of Patent: February 18, 2014
    Assignees: MUSC Foundation for Research Development, National Jewish Health, The Regents of the University of Colorado, a body corporate
    Inventors: Vernon Michael Holers, Joshua M. Thurman, Christian Taube, Erwin W. Gelfand, Gary Steven Gilkeson
  • Patent number: 7999082
    Abstract: Disclosed are novel inhibitors of the alternative complement pathway and particularly, novel anti-factor B antibodies. Also disclosed is the use of such inhibitors to reduce or prevent airway hyperresponsiveness and/or airway inflammation by selectively inhibiting the alternative complement pathway, thereby treating diseases in which such conditions play a role. Also disclosed is the use of such inhibitors to reduce or prevent other diseases and conditions, including ischemia-reperfusion injury, by inhibition of the alternative complement pathway.
    Type: Grant
    Filed: February 10, 2005
    Date of Patent: August 16, 2011
    Assignees: National Jewish Medical and Research Center, MUSC Foundation for Research Development, The Regents of the University of Coloraodo
    Inventors: Vernon Michael Holers, Joshua M. Thurman, Christian Taube, Erwin W. Gelfand, Gary Steven Gilkeson
  • Publication number: 20080102040
    Abstract: Disclosed are novel inhibitors of the alternative complement pathway and particularly, novel anti-factor B antibodies. Also disclosed is the use of such inhibitors to reduce or prevent airway hyperresponsiveness and/or airway inflammation by selectively inhibiting the alternative complement pathway, thereby treating diseases in which such conditions play a role. Also disclosed is the use of such inhibitors to reduce or prevent other diseases and conditions, including ischemia-reperfusion injury, by inhibition of the alternative complement pathway.
    Type: Application
    Filed: August 22, 2007
    Publication date: May 1, 2008
    Inventors: V. Holers, Joshua Thurman, Christian Taube, Erwin Gelfand, Gary Gilkeson
  • Publication number: 20080075720
    Abstract: Disclosed are novel inhibitors of the alternative complement pathway and particularly, novel anti-factor B antibodies. Also disclosed is the use of such inhibitors to reduce or prevent airway hyperresponsiveness and/or airway inflammation by selectively inhibiting the alternative complement pathway, thereby treating diseases in which such conditions play a role. Also disclosed is the use of such inhibitors to reduce or prevent other diseases and conditions, including ischemia-reperfusion injury, by inhibition of the alternative complement pathway.
    Type: Application
    Filed: August 3, 2007
    Publication date: March 27, 2008
    Inventors: Vernon Holers, Joshua Thurman, Christian Taube, Erwin Gelfand, Gary Gilkeson
  • Publication number: 20050260198
    Abstract: Disclosed are novel inhibitors of the alternative complement pathway and particularly, novel anti-factor B antibodies. Also disclosed is the use of such inhibitors to reduce or prevent airway hyperresponsiveness and/or airway inflammation by selectively inhibiting the alternative complement pathway, thereby treating diseases in which such conditions play a role. Also disclosed is the use of such inhibitors to reduce or prevent other diseases and conditions, including ischemia-reperfusion injury, by inhibition of the alternative complement pathway.
    Type: Application
    Filed: February 10, 2005
    Publication date: November 24, 2005
    Applicants: The Regents of the University of Colorado, National Jewish Medical and Research Center, MUSC Foundation for Research Development
    Inventors: Vernon Holers, Joshua Thurman, Christian Taube, Erwin Gelfand, Gary Gilkeson